Quantifying, displaying and accounting for heterogeneity in the meta-analysis of RCTs using standard and generalised Q statistics

被引:467
作者
Bowden, Jack [1 ,2 ]
Tierney, Jayne F. [1 ]
Copas, Andrew J. [1 ]
Burdett, Sarah [1 ]
机构
[1] MRC Clin Trials Unit, London NW1 2DA, England
[2] MRC Biostat Unit, Cambridge CB2 0SR, England
关键词
RANDOM-EFFECTS MODEL; CONFIDENCE-INTERVALS; BIAS; TRIALS;
D O I
10.1186/1471-2288-11-41
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
100404 [儿少卫生与妇幼保健学];
摘要
Background: Clinical researchers have often preferred to use a fixed effects model for the primary interpretation of a meta-analysis. Heterogeneity is usually assessed via the well known Q and I-2 statistics, along with the random effects estimate they imply. In recent years, alternative methods for quantifying heterogeneity have been proposed, that are based on a 'generalised' Q statistic. Methods: We review 18 IPD meta-analyses of RCTs into treatments for cancer, in order to quantify the amount of heterogeneity present and also to discuss practical methods for explaining heterogeneity. Results: Differing results were obtained when the standard Q and I-2 statistics were used to test for the presence of heterogeneity. The two meta-analyses with the largest amount of heterogeneity were investigated further, and on inspection the straightforward application of a random effects model was not deemed appropriate. Compared to the standard Q statistic, the generalised Q statistic provided a more accurate platform for estimating the amount of heterogeneity in the 18 meta-analyses. Conclusions: Explaining heterogeneity via the pre-specification of trial subgroups, graphical diagnostic tools and sensitivity analyses produced a more desirable outcome than an automatic application of the random effects model. Generalised Q statistic methods for quantifying and adjusting for heterogeneity should be incorporated as standard into statistical software. Software is provided to help achieve this aim.
引用
收藏
页数:12
相关论文
共 45 条
[1]
Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 39 randomized trials [J].
Aabo, K ;
Adams, M ;
Adnitt, P ;
Alberts, DS ;
Athanazziou, A ;
Barley, V ;
Bell, DR ;
Bianchi, U ;
Bolis, G ;
Brady, MF ;
Brodovsky, HS ;
Bruckner, H ;
Buyse, M ;
Canetta, R ;
Chylak, V ;
Cohen, CJ ;
Colombo, N ;
Conte, PF ;
Crowther, D ;
Edmonson, JH ;
Gennatas, C ;
Gilbey, E ;
Gore, M ;
Guthrie, D ;
Kaye, SB ;
Laing, AH ;
Landoni, F ;
Leonard, RC ;
Lewis, C ;
Liu, PY ;
Mangioni, C ;
Marsoni, S ;
Meerpohl, H ;
Omura, GA ;
Parmar, MKB ;
Pater, J ;
Pecorelli, S ;
Presti, M ;
Sauerbrei, W ;
Skarlos, DV ;
Smalley, RV ;
Solomon, HJ ;
Stewart, LA ;
Sturgeon, JFG ;
Tattersall, MHN ;
Wharton, JT ;
Huinink, WWT ;
Tomirotti, M ;
Torri, W ;
Trope, C .
BRITISH JOURNAL OF CANCER, 1998, 78 (11) :1479-1487
[2]
Abol-Enein H, 2003, LANCET, V361, P1927
[3]
ALBERTI W, 1995, BRIT MED J, V311, P899
[4]
[Anonymous], LANCET
[5]
[Anonymous], J STAT PLANNING INFE
[6]
[Anonymous], EUROPEAN UROLOGY
[7]
[Anonymous], LANCET
[8]
[Anonymous], LANCET
[9]
[Anonymous], INT J RAD ONCOLOGY B
[10]
[Anonymous], STAT MED